Medpace (MEDP) Stock Price, News & Analysis

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MEDP shares.
View MEDP analyst ratings or view top-rated stocks.

2 brokerages have issued 1 year price objectives for Medpace's stock. Their MEDP share price targets range from $270.00 to $289.00. On average, they anticipate the company's stock price to reach $277.33 in the next twelve months. This suggests that the stock has a possible downside of 9.5%.
View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts.

Medpace's stock was trading at $212.41 on January 1st, 2023. Since then, MEDP shares have increased by 44.3% and is now trading at $306.53.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our MEDP earnings forecast.

Medpace Holdings, Inc. (NASDAQ:MEDP) announced its quarterly earnings data on Monday, October, 23rd. The company reported $2.22 EPS for the quarter, beating the consensus estimate of $2.05 by $0.17. The company had revenue of $492.50 million for the quarter, compared to the consensus estimate of $475.79 million. Medpace had a net margin of 15.33% and a trailing twelve-month return on equity of 68.48%. The firm's revenue for the quarter was up 28.3% on a year-over-year basis. During the same period last year, the business posted $2.05 earnings per share.

ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Argent Mid Cap ETF (AMID), First Trust Health Care AlphaDEX Fund (FXH), Invesco S&P MidCap Quality ETF (XMHQ), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

Medpace updated its FY23 earnings guidance on Monday, October, 23rd. The company provided earnings per share (EPS) guidance of $8.54-8.66 for the period, compared to the consensus estimate of $8.39. The company issued revenue guidance of $1.87-1.89 billion, compared to the consensus revenue estimate of $1.87 billion.

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.